1.Identification of quality markers of Gei Herba based on analytic hierarchy process-entropy weight method and network pharmacology.
Zhao YANG ; Zhi-Bo ZHENG ; Hao-Ming ZHOU ; Ding-Qiao XU ; Shi-Jun YUE ; Yu-Ping TANG
China Journal of Chinese Materia Medica 2023;48(20):5450-5459
Analytic hierarchy process(AHP)-entropy weight method(EWM) and network pharmacology were employed to identify the potential quality markers(Q-markers) of Gei Herba. According to the new concept of Q-markers in traditional Chinese medicine(TCM), the AHP-EWM was applied to quantitatively identify the Q-markers of Gei Herba. The AHP was used for the weight analysis of primary indicators(factor layer), and the EWM for the analysis of literature and experimental data of secondary indicators(control layer). In addition, network pharmacology was employed to build the "component-target-disease-efficacy" network for Gei Herba, and the components showing strong associations with the Qi-replenishing, spleen-invigorating, blood-tonifying, Yin-nourishing, lung-moistening, and phlegm-resolving effects of Gei Herba were screened out. According to the results of AHP-EWM and network pharmacology, four components, i.e., ellagic acid, gallic acid, gemin G, and gemin C, were finally identified as potential Q-markers of Gei Herba. In this study, the AHP-EWM and network pharmacology were employed to screen the Q-markers of Gei Herba, which provided ideas for the quantitative evaluation and identification of Q-markers of TCM.
Drugs, Chinese Herbal/pharmacology*
;
Network Pharmacology
;
Analytic Hierarchy Process
;
Entropy
;
Medicine, Chinese Traditional
2.Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles.
Wen Yu SHAO ; You Ting DONG ; Qiao Ying LYU ; Jiong Bo LIAO ; Yu XUE ; Xiao Jun CHEN
Chinese Journal of Obstetrics and Gynecology 2023;58(10):742-754
Objective: To investigate the impact of molecular classification and key oncogenes on the oncologic outcomes in patients with endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) receiving fertility-preserving treatment. Methods: Patients with EC and AEH undergoing progestin-based fertility-preserving treatment and receiving molecular classification as well as key oncogenes test at Obstetrics and Gynecology Hospital, Fudan University from January 2021 to March 2023 were reviewed. Hysteroscopic lesion resection and endometrial biopsy were performed before initiating hormone therapy and every 3 months during the treatment to evaluate the efficacy. The risk factors which had impact on the treatment outcomes in EC and AEH patients were further analyzed. Results: Of the 171 patients analyzed, the median age was 32 years, including 86 patients with EC and 85 patients with AEH. The distribution of molecular classification was as follows: 157 cases (91.8%) were classified as having no specific molecular profile (NSMP); 9 cases (5.3%), mismatch repair deficient (MMR-d); 3 cases (1.8%), POLE-mutated; 2 cases (1.2%), p53 abnormal. No difference was found in the cumulative 40-week complete response (CR) rate between the patients having NSMP or MMR-d (61.6% vs 60.0%; P=0.593), while the patients having MMR-d had increased risk than those having NSMP to have recurrence after CR (50.0% vs 14.4%; P=0.005). Multi-variant analysis showed PTEN gene multi-loci mutation (HR=0.413, 95%CI: 0.259-0.658; P<0.001) and PIK3CA gene mutation (HR=0.499, 95%CI: 0.310-0.804; P=0.004) were associated with a lower cumulative 40-week CR rate, and progestin-insensitivity (HR=3.825, 95%CI: 1.570-9.317; P=0.003) and MMR-d (HR=9.014, 95%CI: 1.734-46.873; P=0.009) were independent risk factors of recurrence in EC and AEH patients. Conclusions: No difference in cumulative 40-week CR rate is found in the patients having NSMP or MMR-d who received progestin-based fertility-preserving treatment, where the use of hysteroscopy during the treatment might be the reason, while those having MMR-d have a higher risk of recurrence after CR. Oncogene mutation of PTEN or PIK3CA gene might be associated with a lower response to progestin treatment. The molecular profiles help predict the fertility-preserving treatment outcomes in EC and AEH patients.
Pregnancy
;
Female
;
Humans
;
Adult
;
Hyperplasia
;
Progestins
;
Fertility Preservation
;
Endometrial Neoplasms/pathology*
;
Endometrial Hyperplasia/surgery*
;
Treatment Outcome
;
Precancerous Conditions
;
Fertility
;
Class I Phosphatidylinositol 3-Kinases
;
Retrospective Studies
3. Dorsal root ganglion receptor subtype P2X3R mediates postoperative-hyperalgesic priming in mice
Si-Jia ZHEN ; Bei ZHAO ; Bo-Xi ZHENG ; Shu-Xin TIAN ; Ting XU ; Ming-Hui WU ; Jun-Fan FANG ; Jun-Ying DU ; Chi XU ; Jian-Qiao FANG ; Yi LIANG ; Jie ZHOU ; Jian-Qiao FANG ; Yi LIANG
Chinese Pharmacological Bulletin 2023;39(7):1282-1288
Aim To investigate the differences in the role of different purinergic receptor subtypes at different sites in postoperative-hyperalgesic priming in mice. Methods A postoperative-hyperalgesic priming model was constructed by injecting PGE
4.Acupuncture for chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.
Bo LI ; Dong-Dong WANG ; Xiao-di QIAO ; Ai-Hong YUAN ; Ping JIANG ; Jiu-Ping XU ; Jun YANG ; Qing-Ping ZHANG
Chinese Acupuncture & Moxibustion 2023;43(6):654-658
OBJECTIVE:
To observe the short-term efficacy, long-term efficacy and safety of acupuncture for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
METHODS:
Forty-two patients with CP/CPPS were randomly divided into an acupuncture group (21 cases, 1 case dropped off) and a sham acupuncture group (21 cases). The patients in the acupuncture group were treated with acupuncture at bilateral Zhongliao (BL 33), Huiyang (BL 35), Shenshu (BL 23) and Sanyinjiao (SP 6); the needling depth of Zhongliao (BL 33) and Huiyang (BL 35) was 60 to 80 mm, while Shenshu (BL 23) and Sanyinjiao (SP 6) was directly punctured of 30 mm. The patients in the sham acupuncture group were treated with acupuncture at non-acupoints, including points 2 cm next to Shenshu (BL 23), Zhongliao (BL 33) and Huiyang (BL 35), and the midpoint of the connecting line between the spleen meridian and the kidney meridian. All the non-acupoints were treated with directly puncture of 2 to 3 mm. The needles were left for 30 min in both groups, once every other day in the first four weeks, three times a week, and twice a week in the next four weeks, totally 20 treatments. Before treatment, after treatment and in follow-up of 24 weeks after treatment completion, the National Institutes of Health-chronic prostatitis symptom index (NIH-CPSI) score and urinary flow rate were observed in both groups; the clinical efficacy and safety were evaluated.
RESULTS:
Compared with those before treatment, the pain and discomfort scores, urination symptoms scores, quality of life scores and total scores of NIH-CPSI in both groups were reduced after treatment in the two groups (P<0.01), while each item score and total score of NIH-CPSI in the acupuncture group were reduced in follow-up (P<0.01, P<0.05). After treatment and in follow-up, each item score and total score of NIH-CPSI in the acupuncture group were lower than those in the sham acupuncture group (P<0.05, P<0.01). After treatment, the maximum and average urinary flow rates in the acupuncture group were higher than those before treatment (P<0.05), and the average urinary flow rate in the acupuncture group was higher than that in the sham acupuncture group (P<0.05). The total effective rate was 75.0% (15/20) in the acupuncture group, which was higher than 42.9% (9/21) in the sham acupuncture group (P<0.05). No significant adverse reactions were observed in the two groups, and there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
CONCLUSION
Acupuncture could effectively alleviate the clinical symptoms, improve quality of life, and has a sustained, safe and reliable therapeutic effect in patients with CP/CPPS.
United States
;
Male
;
Humans
;
Prostatitis/therapy*
;
Quality of Life
;
Acupuncture Therapy
;
Punctures
;
Meridians
5.Characterization of Microbiota in Tumor Tissues of Esophageal Squamous Cell Carcinoma
Bo-hong XIAN ; Jun-min WEI ; Gui-bin QIAO ; Xiao-hui CHEN ; Fang-ping XU ; Xin-lan LUO ; Yi-xiang CHEN ; Zi-jun LI
Journal of Sun Yat-sen University(Medical Sciences) 2022;43(3):480-487
ObjectiveTo analyze the difference in esophageal microbiome between the patients with esophageal squamous cell carcinoma (ESCC group) and the healthy controls (HC group), and to screen out the characteristic bacteria in tumor tissues of patients with esophageal squamous cell carcinoma. MethodsEsophageal tissues were collected from 105 patients with esophageal squamous cell carcinoma and 54 healthy controls. The total DNA of the samples was extracted, and the 16S rDNA V4 region was amplified by PCR, followed by high-throughput sequencing. The data were subjected to OTU clustering and diversity analysis to screen the characteristic bacteria in the ESCC group. Finally, the screening results were to be verified by Q-PCR amplification. ResultsDiversity analysis showed that there were differences in diversity and composition between the ESCC group and the HC group. Species analysis showed that the main components of microbiome in the ESCC group were Fusobacterium, Gemella, Neisseria, Porphyromonas and Streptococcus. While in the HC group the main components of microbiome were Fusobacterium, Actinobacillus, Streptococcus and Prevotella. The LEfSe analysis showed that the expression of porphyrin and Fusobacteria in the ESCC group increased and the difference is statistically significant (P<0.05). The results of Q-PCR showed that the presence of Porphyromonas gingivalis and Fusobacterium nucleatum in the ESCC group significantly increased. ConclusionsEsophageal cancer has its characteristic flora composition. Porphyromonas gingivalis and Fusobacterium nucleatum in esophageal squamous cell carcinoma tumor tissue are the characteristic bacteria.
6.Research on antitumor effects of small molecule inhibitors of deubiquitinases: new progress and new ideas
Xiang-ning LIU ; Jia-min DU ; Mei-jia QIAN ; Xiao-wu DONG ; Bo YANG ; Hong ZHU ; Qiao-jun HE
Acta Pharmaceutica Sinica 2022;57(3):547-556
The abnormality of ubiquitin proteasome pathway is an important factor leading to the imbalance of protein homeostasis. In this process, the deubiquitinase responsible for removing the ubiquitin chain of protein substrate is very important. Its abnormal activity or expression can cause the functional changes of key oncogenic/tumor suppressor proteins, which directly or indirectly lead to the occurrence, development and malignant evolution of tumors. Based on this, the discovery and research of small molecule inhibitors targeting deubiquitinases have become a hot field of anti-tumor candidate drugs. This review will focus on the regulatory effect and mechanism of ubiquitin proteasome pathway, especially deubiquitinase on tumor, introduce the application of deubiquitinase small molecule inhibitors in tumor treatment, and discuss the research status and latest progress of small molecule inhibitors, so as to provide ideas for the research of new anti-tumor strategies based on deubiquitinase.
7.Recent advances in mechanisms of KRASG12C inhibitors anti-tumor resistance and relevant overcoming strategies
Ke-xin LIU ; Rui-lin WU ; Tao YUAN ; Kai-yue PU ; Qiao-jun HE ; Hong ZHU ; Bo YANG
Acta Pharmaceutica Sinica 2022;57(2):271-276
KRAS is one of the most frequently mutated human oncogenes. In spite of mounting efforts on the development of direct or indirect inhibition targeting KRAS, little has been achieved because of insurmountable difficulties, titling KRAS "undruggable". Recently, subtype-specific inhibitors have shown great hope. Some KRASG12C inhibitors have entered clinical trials, including adagrasib and sotorasib, and have shown preliminary clinical effectiveness. Experiences from the inhibitors targeting the downstream factors of RAS pathways show that the anticancer activity of these drugs will be limited due to the development of drug resistance. Preclinical studies of KRASG12C inhibitors have revealed that the application of these agents might be hampered by the drug resistance issue. The current review aims to describe the current status of KRASG12C inhibitors, and discuss the mechanisms underlying KRASG12C inhibitor resistance, so as to provide the clues for the combat of drug resistance.
8.Analysis on infection risk in secondary close contacts of COVID-19 patients.
Bo YI ; Yan Ru CHU ; Yi CHEN ; Dong Liang ZHANG ; Yan Wu ZHANG ; Song LEI ; Lu HONG ; Qiao Fang LI ; Xiao Min GU ; Xu Ying LAO ; Hai Bo WANG ; Jun Fen LIN ; Guozhang XU
Chinese Journal of Epidemiology 2022;43(8):1237-1240
Objective: To study the infection rate of secondary close contacts of COVID-19 patients, and assess the infection risk in the contacts. Methods: COVID-19 patients' close contacts (with a clear exposure time to index case) with negative nucleic acid test results and secondary close contacts were surveyed in continuous isolation and medical observation in this prospective study. The dynamic nucleic acid test results of the close contacts and secondary contacts of COVID-19 patients were collected to assess their risk of infection. Results: A total of 4 533 close contacts were surveyed, in whom 14 were confirmed as COVID-19 patients with overall secondary attack rate of 0.31%, and 4 201 secondary contacts were tracked, in whom no subsequent infections occurred. Conclusion: Close contacts of COVID-19 patients entered in centralized isolation for medical observation with negative nucleic acid tese results,the secondary close contacts of COVID-19 patients have no risk of infection.
COVID-19/epidemiology*
;
Contact Tracing
;
Humans
;
Incidence
;
Nucleic Acids
;
Prospective Studies
;
SARS-CoV-2
10.Consensus on clinical management of tumor-induced osteomalacia.
Yan JIANG ; Xiang LI ; Li HUO ; Yong LIU ; Wei LYU ; Lian ZHOU ; Wei YU ; Huan-Wen WU ; Xiao-Ping XING ; Mei LI ; Ou WANG ; Yue CHI ; Rui-Zhi JIAJUE ; Yu PEI ; Jian-Min LIU ; Jian-Ming BA ; Qiao ZHANG ; Zhi-Feng SHENG ; Zhen-Lin ZHANG ; Jia-Jun ZHAO ; Salvatore MINISOLA ; Wei-Bo XIA
Chinese Medical Journal 2021;134(11):1264-1266

Result Analysis
Print
Save
E-mail